Last reviewed · How we verify
Coenzyme Q10 (drug)
Coenzyme Q10 acts as an electron carrier in the mitochondrial electron transport chain, facilitating ATP production and providing antioxidant protection.
Coenzyme Q10 acts as an electron carrier in the mitochondrial electron transport chain, facilitating ATP production and providing antioxidant protection. Used for Heart failure, Hypertension, Statin-induced myopathy.
At a glance
| Generic name | Coenzyme Q10 (drug) |
|---|---|
| Sponsor | University of Shizuoka |
| Drug class | Mitochondrial cofactor / Antioxidant |
| Target | Mitochondrial electron transport chain (Complexes I-III, Complex IV) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular, Neurology, Metabolic disorders |
| Phase | FDA-approved |
Mechanism of action
Coenzyme Q10 (ubiquinone) is an endogenous cofactor essential for cellular energy metabolism, particularly in the inner mitochondrial membrane where it shuttles electrons between complexes I-III and complex IV. It also functions as a lipophilic antioxidant, scavenging free radicals and protecting cellular membranes from oxidative damage. These dual roles support cellular bioenergetics and reduce oxidative stress in tissues with high metabolic demands.
Approved indications
- Heart failure
- Hypertension
- Statin-induced myopathy
- Migraine prophylaxis
- Parkinson's disease (investigational)
Common side effects
- Gastrointestinal upset
- Nausea
- Headache
- Insomnia
Key clinical trials
- Renoprotective Role of Vitamin C and Coenzyme Q10 in Nephrotoxicity (PHASE2, PHASE3)
- The Effect of Co-enzyme Q10 on the Clinical Outcome of Pediatric Patients With Systemic Lupus Erythematosus (PHASE2)
- Coenzyme Q10 for Neuroprotection in Paclitaxel-Induced Neuropathy (PHASE2)
- Reducing Fatigue With CoQ10 Supplementation in Patients With Crohn's Disease Study (EARLY_PHASE1)
- Coenzyme Q10 in Pediatric Community-Acquired Pneumonia (NA)
- CoQ10 and Exercise for Mitochondrial Dysfunction in Advance Kidney Disease (PHASE3)
- Coenzyme Q10 and Chemotherapeutic Toxicity in Breast Cancer Patients (PHASE2)
- The Effects of Coenzyme Q10 Pretreatment on Ovarian Function and Assisted Reproductive Outcomes in Patients With Ovarian Hyporesponsiveness. (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Coenzyme Q10 (drug) CI brief — competitive landscape report
- Coenzyme Q10 (drug) updates RSS · CI watch RSS
- University of Shizuoka portfolio CI